Breast Cancer Diagnostics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Breast Cancer Diagnostics Market will record a 10.2% CAGR over 2024-2032, owing to increasing awareness about the ailment and a growing demand for early detection solutions. According to the WHO, in 2022, there were 2.3 million women diagnosed with breast cancer globally, and the disease resulted in approximately 670,000 deaths. Advances in medical technology have led to tools like digital mammography, 3D tomosynthesis, and molecular imaging, which enhance detection accuracy and patient outcomes through earlier interventions and personalized treatments.

Government and NGO initiatives significantly contribute to market growth. Public health campaigns, awareness programs, and improved healthcare infrastructure promote routine screenings and diagnostic testing. For instance, the American Cancer Society reported a 64% increase in early-stage breast cancer detection due to widespread screening programs. Additionally, integrating AI and ML into diagnostics offers greater precision and speed. Healthcare providers and patients seeking advanced solutions will shape the market dynamics.

The overall breast cancer diagnostics market is classified based on product, test type, cancer type, application, end-user, and region.

The genomic tests segment is rapidly gaining traction due to its ability to provide personalized insights into the genetic underpinnings of breast cancer. These tests, such as Oncotype DX, MammaPrint, and PAM50, analyze the expression of specific genes within tumor cells to assess the likelihood of cancer recurrence and the potential effectiveness of various treatments. By offering tailored prognostic and predictive information, genomic tests enable clinicians to make more informed decisions regarding treatment strategies, thereby enhancing patient outcomes and optimizing therapeutic approaches.

The prognostic segment will hold a notable market share by 2032. Prognostic tests assess the likely course of the disease based on various factors, including tumor characteristics and genetic markers. These tests help determine the risk of cancer recurrence and the potential benefit of specific treatments, allowing for a more personalized and effective approach to patient management. By providing insights into the aggressiveness of cancer and potential responses to therapy, prognostic applications enable healthcare providers to tailor treatment plans, prioritize intervention strategies, and improve overall patient prognosis, thereby driving the demand for advanced diagnostic solutions in this segment.

Europe breast cancer diagnostics market is set to experience robust growth through 2032, driven by increasing awareness of breast cancer, advancements in diagnostic technologies, and supportive healthcare policies. European countries are implementing comprehensive screening programs and investing in state-of-the-art diagnostic tools, such as digital mammography and molecular imaging, to enhance early detection and treatment. Additionally, the region's strong emphasis on R and D, coupled with collaborative efforts among public and private sectors, is fostering innovation in diagnostic solutions. With a rising focus on personalized medicine and improved access to advanced diagnostic technologies, the European market is poised for continued expansion.

Product Code: 10383

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of breast cancer globally
  - 3.2.1.2 Technological advancements in breast cancer diagnostics
  - 3.2.1.3 Rising government initiatives and awareness programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of diagnostic tests
  - 3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTLE analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
5.3 Kits and consumables

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Imaging
- 6.2.1 Mammography
- 6.2.2 MRI
- 6.2.3 Ultrasound
- 6.2.4 PET/CT
6.3 Biopsy
6.4 Genomic tests
6.5 Blood tests
6.6 Other test types

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Ductal carcinoma in situ
7.3 Invasive ductal carcinoma
7.4 Inflammatory breast cancer
7.5 Metastatic breast cancer

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Screening
8.3 Diagnostic and predictive
8.4 Prognostic
8.5 Research

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals and clinics
9.3 Diagnostic centers
9.4 Cancer research institutes
9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

11.1 Argon Medical Devices
11.2 Becton, Dickinson and Company
11.3 Bio-Rad Laboratories, Inc.
11.4 Canon Inc.
11.5 Danaher Corporation
11.6 Exact Sciences Corporation
11.7 F. Hoffmann-La Roche Ltd
11.8 FUJIFILM Holdings Corporation
11.9 Hologic, Inc.
11.10 Illumina, Inc.
11.11 Koninklijke Philips N.V.
11.12 Myriad Genetics, Inc.
11.13 QIAGEN N.V.
11.14 Siemens Healthineers AG
11.15 Thermo Fisher Scientific Inc.